The ‘amine’ ergot alkaloid differs from ‘amino acid’ ergot alkaloid in that it has: A. High oral bioavailability B. Better CNS penetrability C. Weaker oxytocic action D. Strong anti-5-HT action

The ‘amine’ ergot alkaloid differs from ‘amino acid’ ergot alkaloid in that it has: A. High oral bioavailability B. Better CNS penetrability C. Weaker oxytocic action D. Strong anti-5-HT action
by

1 Answer

Answer :

A. High oral bioavailability
by

Related questions

Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Description : Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Last Answer : D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Description : The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Last Answer : C. Cyproheptadine

The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Description : The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Last Answer : C. Cyproheptadine

The smooth muscle stimulating action of 5-HT is most marked in the: A. Bronchi B. Intestines C. Ureter D. Biliary tract

Description : The smooth muscle stimulating action of 5-HT is most marked in the: A. Bronchi B. Intestines C. Ureter D. Biliary tract

Last Answer : B. Intestines

The following is a selective 5-HT1D receptor agonist: A. Buspirone B. Ondansetron C. Sumatriptan D. α-methyl 5-HT

Description : The following is a selective 5-HT1D receptor agonist: A. Buspirone B. Ondansetron C. Sumatriptan D. α-methyl 5-HT

Last Answer : C. Sumatriptan

Choose the ergot alkaloid that is well absorbed orally, has weak vascular but prominent uterine stimulant action: A. Ergometrine B. Ergotamine C. Dihydroergotamine D. Dihydroergotoxine

Description : Choose the ergot alkaloid that is well absorbed orally, has weak vascular but prominent uterine stimulant action: A. Ergometrine B. Ergotamine C. Dihydroergotamine D. Dihydroergotoxine

Last Answer : A. Ergometrine

Fexofenadine differs from terfenadine in that: A. It undergoes high first pass metabolism in liver B. It is a prodrug C. It does not block cardiac delayed rectifier K+ channels D. It has high affinity for central H1 receptors

Description : Fexofenadine differs from terfenadine in that: A. It undergoes high first pass metabolism in liver B. It is a prodrug C. It does not block cardiac delayed rectifier K+ channels D. It has high affinity for central H1 receptors

Last Answer : C. It does not block cardiac delayed rectifier K+ channels

Hyoscine differs from atropine in that it (a) Exerts depressant effects on the CNS at relatively low doses (b) Exerts more potent effects on the heart than on the eye (c) Is longer acting (d) Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it (a) Exerts depressant effects on the CNS at relatively low doses (b) Exerts more potent effects on the heart than on the eye (c) Is longer acting (d) Has weaker antimotion sickness activity

Last Answer : Ans: A

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Description : Hyoscine differs from atropine in that it: A. Exerts depressant effects on the CNS at relatively low doses B. Exerts more potent effects on the heart than on the eye C. Is longer acting D. Has weaker antimotion sickness activity

Last Answer : A. Exerts depressant effects on the CNS at relatively low doses

Nonsteroidal antiinflammatory drugs are more commonly used than colchicine in acute gout because: A. They are more effective B. They act more rapidly C. They have additional uricosuric action D. They are better tolerated

Description : Nonsteroidal antiinflammatory drugs are more commonly used than colchicine in acute gout because: A. They are more effective B. They act more rapidly C. They have additional uricosuric action D. They are better tolerated

Last Answer : D. They are better tolerated

The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Description : The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Last Answer : B. Direct action on vascular smooth muscle causing vasodilatation

Probenecid has the following action(s): A. Uricosuric B. Analgesic C. Antiinflammatory D. Both ‘A’ and ‘C’

Description : Probenecid has the following action(s): A. Uricosuric B. Analgesic C. Antiinflammatory D. Both ‘A’ and ‘C’

Last Answer : A. Uricosuric

Phenylbutazone should be used only in patients not responding to other nonsteroidal antiinflammatory drugs (NSAIDs) because: A. It has lower antiinflammatory efficacy than other NSAIDs B. It has potential to cause agranulocytosis C. It has weak analgesic action D. It alters the protein binding and metabolism of many drugs

Description : Phenylbutazone should be used only in patients not responding to other nonsteroidal antiinflammatory drugs (NSAIDs) because: A. It has lower antiinflammatory efficacy than other NSAIDs B. It has potential ... It has weak analgesic action D. It alters the protein binding and metabolism of many drugs

Last Answer : B. It has potential to cause agranulocytosis

Inhibition of prostaglandin synthesis does not underlie the following action of aspirin: A. Analgesia B. Closure of patent ductus arteriosus C. Hyperventilation D. Bleeding tendency

Description : Inhibition of prostaglandin synthesis does not underlie the following action of aspirin: A. Analgesia B. Closure of patent ductus arteriosus C. Hyperventilation D. Bleeding tendency

Last Answer : C. Hyperventilation

Montelukast blocks the action of the following autacoid: A. Prostacyclin B. Platelet activating factor C. Leukotriene B4 D. Leukotriene C4/D4

Description : Montelukast blocks the action of the following autacoid: A. Prostacyclin B. Platelet activating factor C. Leukotriene B4 D. Leukotriene C4/D4

Last Answer : D. Leukotriene C4/D4

The most prominent action of leukotriene B4 is: A. Vasodilatation B. Uterine contraction C. Platelet aggregation D. Chemotaxis of neutrophils and monocytes

Description : The most prominent action of leukotriene B4 is: A. Vasodilatation B. Uterine contraction C. Platelet aggregation D. Chemotaxis of neutrophils and monocytes

Last Answer : D. Chemotaxis of neutrophils and monocytes

Erythromycin should not be given to a patient being treated with terfenadine because: A. Erythromycin induces the metabolism of terfenadine B. Dangerous ventricular arrhythmias can occur C. Terfenadine inhibitis metabolism of erythromycin D. Terfenadine antagonizes the antimicrobial action of erythromycin

Description : Erythromycin should not be given to a patient being treated with terfenadine because: A. Erythromycin induces the metabolism of terfenadine B. Dangerous ventricular arrhythmias ... Terfenadine inhibitis metabolism of erythromycin D. Terfenadine antagonizes the antimicrobial action of erythromycin

Last Answer : B. Dangerous ventricular arrhythmias can occur

The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Description : The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Last Answer : B. Direct action on vascular smooth muscle causing vasodilatation

A 35-year-old male presented with an attack of acute gout. He was treated with a 10 day course of naproxen. His blood uric acid level is high. What future line of treatment is most appropriate: A. No regular medication. Treat attacks of acute gout when they occur with naproxen. B. Regular long-term treatment with naproxen C. Regular long-term treatment with allopurinol D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

Description : A 35-year-old male presented with an attack of acute gout. He was treated with a 10 day course of naproxen. His blood uric acid level is high. What future line of treatment is ... treatment with allopurinol D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

Last Answer : D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Last Answer : Ans: A

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action

Allopurinol is indicated in the following category of chronic gout patients: A. Over producers of uric acid B. Under excretors of uric acid C. Those with tophi and/or renal urate stones D. All of the above

Description : Allopurinol is indicated in the following category of chronic gout patients: A. Over producers of uric acid B. Under excretors of uric acid C. Those with tophi and/or renal urate stones D. All of the above

Last Answer : D. All of the above

Which of the following analgesics itself frequently causes headache as a side effect: A. Indomethacin B. Mephenamic acid C. Piroxicam D. Metamizol

Description : Which of the following analgesics itself frequently causes headache as a side effect: A. Indomethacin B. Mephenamic acid C. Piroxicam D. Metamizol

Last Answer : A. Indomethacin

In the treatment of chronic inflammatory diseases, the most important limitation of aspirin is: A. Acid-base and electrolyte disturbances B. Hypersensitivity and idiosyncratic reactions C. Gastric mucosal damage D. Salicylism

Description :  In the treatment of chronic inflammatory diseases, the most important limitation of aspirin is: A. Acid-base and electrolyte disturbances B. Hypersensitivity and idiosyncratic reactions C. Gastric mucosal damage D. Salicylism

Last Answer : C. Gastric mucosal damage

Select the drug which inhibits cyclooxygenase irreversibly: A. Aspirin B. Mephenamic acid C. Naproxen D. Diclofenac

Description : Select the drug which inhibits cyclooxygenase irreversibly: A. Aspirin B. Mephenamic acid C. Naproxen D. Diclofenac

Last Answer : A. Aspirin

Actions of prostaglandin E2 include the following except: A. Fall in blood pressure B. Bronchoconstriction C. Uterine contraction D. Inhibition of gastric acid secretion

Description : Actions of prostaglandin E2 include the following except: A. Fall in blood pressure B. Bronchoconstriction C. Uterine contraction D. Inhibition of gastric acid secretion

Last Answer : B. Bronchoconstriction

High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Description : High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Last Answer : A. Diphenhydramine

High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Description : High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Last Answer : A. Diphenhydramine

Out of two anticholinesterases, drug ‘X’ is a tertiary amine while drug ‘Y’ is a quarternary ammonium compound. Then: A. Drug ‘X’ is likely to be more potent than ‘Y’ B. Drug ‘X’ will be more suitable to be used as a miotic C. Drug ‘Y’ will be completely metabolized in the body D. Drug ‘Y’ will produce CNS effects

Description : Out of two anticholinesterases, drug X' is a tertiary amine while drug Y' is a quarternary ammonium compound. Then: A. Drug X' is likely to be more potent than Y' B. Drug X' will be more ... a miotic C. Drug Y' will be completely metabolized in the body D. Drug Y' will produce CNS effects

Last Answer : B. Drug ‘X’ will be more suitable to be used as a miotic

Out of two anticholinesterases, drug ‘X’ is a tertiary amine while drug ‘Y’ is a quarternary ammonium compound. Then: A. Drug ‘X’ is likely to be more potent than ‘Y’ B. Drug ‘X’ will be more suitable to be used as a miotic C. Drug ‘Y’ will be completely metabolized in the body D. Drug ‘Y’ will produce CNS effects

Description : Out of two anticholinesterases, drug X' is a tertiary amine while drug Y' is a quarternary ammonium compound. Then: A. Drug X' is likely to be more potent than Y' B. Drug X' will be more ... a miotic C. Drug Y' will be completely metabolized in the body D. Drug Y' will produce CNS effects

Last Answer : B. Drug ‘X’ will be more suitable to be used as a miotic

Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Description : Fluconazole differs from ketoconazole in that: A. It is not active by the oral route B. It is a more potent inhibitor of drug metabolism C. It is not effective in cryptococcal meningitis D. It is unlikely to produce anti-androgenic side effects

Last Answer : D. It is unlikely to produce anti-androgenic side effects

Dysmenorrhoea is often associated with excess production of the following autacoid by the endometrium: A. Bradykinin B. Prostaglandin C. Platelet activating factor D. 5-Hydroxytryptamine

Description :  Dysmenorrhoea is often associated with excess production of the following autacoid by the endometrium: A. Bradykinin B. Prostaglandin C. Platelet activating factor D. 5-Hydroxytryptamine

Last Answer : B. Prostaglandin

The following serotonergic receptor functions primarily as an autoreceptor on neurones: A. 5-HT1A B. 5-HT2A C. 5-HT3 D. 5-HT4

Description : The following serotonergic receptor functions primarily as an autoreceptor on neurones: A. 5-HT1A B. 5-HT2A C. 5-HT3 D. 5-HT4

Last Answer : A. 5-HT1A

Actions of 5-HT2 receptor activation are primarily mediated by: A. Increased membrane permeability to Na+ ions B. Increased formation of cAMP C. Activation of guanylyl cyclase D. Generation of inositol trisphosphate and diacyl glycerols

Description : Actions of 5-HT2 receptor activation are primarily mediated by: A. Increased membrane permeability to Na+ ions B. Increased formation of cAMP C. Activation of guanylyl cyclase D. Generation of inositol trisphosphate and diacyl glycerols

Last Answer : D. Generation of inositol trisphosphate and diacyl glycerols

Venlafaxine differs from standard tricyclic antidepressants in that it: A. Does not inhibit 5-HT reuptake B. Does not inhibit noradrenaline reuptake C. Does not have anticholinergic or antiadrenergic property D. Has lower antidepressant efficacy

Description : Venlafaxine differs from standard tricyclic antidepressants in that it: A. Does not inhibit 5-HT reuptake B. Does not inhibit noradrenaline reuptake C. Does not have anticholinergic or antiadrenergic property D. Has lower antidepressant efficacy

Last Answer : C. Does not have anticholinergic or antiadrenergic property

While prescribing a first generation H1 antihistaminic the patient should be advised to avoid: A. Driving motor vehicles B. Consuming processed cheese C. Strenuous physical exertion D. All of the above

Description : While prescribing a first generation H1 antihistaminic the patient should be advised to avoid: A. Driving motor vehicles B. Consuming processed cheese C. Strenuous physical exertion D. All of the above

Last Answer : A. Driving motor vehicles

The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Last Answer : D. Ratio of H1:H2 blockade produced by the drug

The conventional H1 antihistaminics possess the following additional properties except: A. Local anaesthetic B. Vasopressor C. Antiarrhythmic D. Catecholamine potentiating

Description : The conventional H1 antihistaminics possess the following additional properties except: A. Local anaesthetic B. Vasopressor C. Antiarrhythmic D. Catecholamine potentiating

Last Answer : B. Vasopressor

Which of the following is a selective H1 receptor agonist: A. 4-methyl histamine B. Impromidine C. 2-Thiazolyl ethylamine D. Chlorpheniramine

Description : Which of the following is a selective H1 receptor agonist: A. 4-methyl histamine B. Impromidine C. 2-Thiazolyl ethylamine D. Chlorpheniramine

Last Answer : C. 2-Thiazolyl ethylamine

Autacoids differ from hormones in that: A. Autacoids are involved only in the causation of pathological states B. Autacoids do not have a specific cell/tissue of origin C. Autacoids generally act locally at the site of generation and release D. Both ‘B’ and ‘C’ are correct

Description : Autacoids differ from hormones in that: A. Autacoids are involved only in the causation of pathological states B. Autacoids do not have a specific cell/tissue of origin C. Autacoids generally act locally at the site of generation and release D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Allopurinol has a therapeutic effect in the following conditions except: A. Radiotherapy induced hyperuricaemia B. Hydrochlorothiazide induced hyperuricaemia C. Acute gouty arthritis D. Kala-azar

Description : Allopurinol has a therapeutic effect in the following conditions except: A. Radiotherapy induced hyperuricaemia B. Hydrochlorothiazide induced hyperuricaemia C. Acute gouty arthritis D. Kala-azar

Last Answer : C. Acute gouty arthritis

Select the drug which is used in chronic gout but is not uricosuric: A. Probenecid B. Phenylbutazone C. Sulfinpyrazone D. Allopurinol

Description : Select the drug which is used in chronic gout but is not uricosuric: A. Probenecid B. Phenylbutazone C. Sulfinpyrazone D. Allopurinol

Last Answer : D. Allopurinol

The most important dose-limiting adverse effect of colchicine is: A. Sedation B. Kidney damage C. Diarrhoea D. Muscle paralysis

Description : The most important dose-limiting adverse effect of colchicine is: A. Sedation B. Kidney damage C. Diarrhoea D. Muscle paralysis

Last Answer : C. Diarrhoea

Select the drug which is neither analgesic, nor antiinflammatory, nor uricosuric, but is highly efficacious in acute gout: A. Prednisolone B. Colchicine C. Naproxen D. Sulfinpyrazone

Description : Select the drug which is neither analgesic, nor antiinflammatory, nor uricosuric, but is highly efficacious in acute gout: A. Prednisolone B. Colchicine C. Naproxen D. Sulfinpyrazone

Last Answer : B. Colchicine

Select the first choice drug for acute gout: A. Cochicine B. Indomethacin C. Allopurinol D. Dexamethasone

Description : Select the first choice drug for acute gout: A. Cochicine B. Indomethacin C. Allopurinol D. Dexamethasone

Last Answer : B. Indomethacin

What is true of disease modifying antirheumatic drugs: A. Their beneficial effect is manifest only after 1-3 months of therapy B. The disease does not recurr once they induce remission C. They are to be used life long D. Concurrent use of more than one disease modifying drug is not recommended

Description : What is true of disease modifying antirheumatic drugs: A. Their beneficial effect is manifest only after 1-3 months of therapy B. The disease does not recurr once they induce remission C. They are to be used life long D. Concurrent use of more than one disease modifying drug is not recommended

Last Answer : A. Their beneficial effect is manifest only after 1-3 months of therapy

Disease modifying antirheumatic drugs are indicated in rheumatoid arthritis: A. In place of NSAIDs in patients who donot tolerate the latter B. Along with NSAIDs in patients with progressive disease C. Only when NSAIDs fail to afford symptomatic relief D. In all patients irrespective of disease status/ concurrent medication

Description : Disease modifying antirheumatic drugs are indicated in rheumatoid arthritis: A. In place of NSAIDs in patients who donot tolerate the latter B. Along with NSAIDs in patients with progressive ... to afford symptomatic relief D. In all patients irrespective of disease status/ concurrent medication

Last Answer : B. Along with NSAIDs in patients with progressive disease